- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01324648
Evaluation of the Bounce Back Program
A Randomized Controlled Trial Evaluation of Brief, Telephone Supported CBT Self-help in Primary Care Patients With Mild to Moderate Depression
Lifetime prevalence rates of Major Depressive Disorder (MDD) in Canada are between 10-12% with approximately 1.5 million Canadians reporting depression in any given year. Alarmingly, the burden of ill health associated with MDD is projected to increase worldwide such that by the year 2020, depression will move from its current position of fourth to become the second greatest burden of ill health, closely following ischaemic heart disease (Murray & Lopez, 1998). As depressed patients are often in frequent contact with their primary care physicians for other health problems, effective depression treatment and management currently relies heavily on the primary care sector. Cognitive behavioural therapy (CBT) is an empirically supported psychotherapy that is recommended by the Canadian Network for Mood and Anxiety Treatments Clinical Guidelines as a first-line treatment for depression. However, across Canada, CBT is not readily accessible by primary care physicians for their patients, particularly in rural areas.
To help address this nationwide need for CBT, British Columbia (BC) is the first and only province in Canada to develop and implement a high capacity mental health service, Bounce Back: Reclaim your Health (BB), for primary care patients with mild to moderate depression. In BB, the patients' use of Cognitive-Behavioural Therapy (CBT) self-help materials is supported via trained telephone coaches.
The primary objective of our proposed research is to provide direct evidence of the effectiveness of the BB program, and, in particular, the telephone coaching component. The investigators will test: (1) whether the BB program is more effective than general practitioner (GP) treatment-as-usual (TAU); and (2) whether BB's positive results can be attributed to the telephone coaching component, as this component is associated with the most significant costs of the program. A secondary objective is to assess the cost-effectiveness of such telephone support.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T3G0B4
- Calgary Foothills Primary Care Network
-
Chinook Valley, Alberta, Canada, T1J013
- Chinook Primary Care Network
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T2A1
- University of British Columbia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- currently experiencing a mild to moderate level of depressive symptoms as defined by a score of 5 - 19 on the PHQ-9;
- 19 years of age or older
- willing to use the BB program;
- able to use the BB self-help materials with telephone coaching (have access to read, hear a telephone conversation and have a telephone); and,
- ability to give informed consent and complete questionnaires unassisted.
Exclusion Criteria:
- a SCID diagnosis (past or present) of: (a) Bipolar Disorder; (b) Schizophreniform Disorders; (c) Substance Abuse or Dependence (current or within the past six months); (d) Borderline or Antisocial Personality Disorder (based on GP's diagnosis); or (e) Cognitive Disorder (as the BB program is not appropriate for these individuals);
- active suicidal intent, (as defined by a score of 2 or more on the BDI-II suicide item #9; those with passive suicidal ideation will be monitored;
- impaired concentration and motivation (scoring 7 or more on the combined BDI-II items #15, 19 and 20 for energy, concentration difficulty and tiredness, respectively);
- are currently receiving, or have received in the previous 6 months, CBT or guided self-help for depression; or,
- are involved in other clinical research studies.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: TG + GP TAU
|
Participants' use of the BB self-help materials will be supported by three to five telephone coaching sessions that occur approximately every 2-3 weeks.
Total contact time will be approximately 2 hours (2 hour total contact time will be considered "brief" in our study).
Participants will also continue to receive whatever current treatment their general practitioner is providing.
|
|
Experimental: UG + GP TAU
|
This treatment was chosen as a control for the telephone coaching component of the BB program.
Participants will be sent a package containing the BB self-help materials and along with instructions on how to utilize these materials.
Participants will use the materials on their own and at their own pace.
Participants will also continue to receive whatever current treatment their general practitioner is providing.
|
|
Active Comparator: GP TAU
|
This group will receive treatment as usual - whereby the clinic staff will inform the participant's GP of their PHQ-9 score.
They will also be informed that their GP will be contacted that they are taking part in the research and that their GP will continue to support them with their depression as usual.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in levels of depressive symptomatology
Time Frame: The PHQ-9 will be assessed at screening, 2 month, 4 month, and 12 month time points.
|
Levels of depressive symptomatology will be measured over time, using the Patient Health Questionnaire (PHQ-9)
|
The PHQ-9 will be assessed at screening, 2 month, 4 month, and 12 month time points.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes of levels of anxiety
Time Frame: The GAD-7 will be assessed at baseline, 2 month, 4 month, and 12 month time points
|
Levels of anxiety will be measured over tiem, using the Generalized Anxiety Disorder 7 (GAD-7).
|
The GAD-7 will be assessed at baseline, 2 month, 4 month, and 12 month time points
|
|
Changes in quality of life and enjoyment
Time Frame: The QLES-Q-SF will be assessed at baseline, 2 month, 4 month, and 12 month time points
|
Quality of life and enjoyment will be measured over time using the Quality of Life and Enjoyment Satisfaction Questionnaire (QLES-Q-SF).
|
The QLES-Q-SF will be assessed at baseline, 2 month, 4 month, and 12 month time points
|
|
Changes in work and social adjustment
Time Frame: The WASA will be assessed at baseline, 2 month, 4 month, and 12 month time points
|
Work and social adjustemnt will be assessed over time, using the Work and Social Adjustment Scale (WASA).
|
The WASA will be assessed at baseline, 2 month, 4 month, and 12 month time points
|
|
Changes in work functionality and impairment
Time Frame: The LEAPS will be assessed at baseline, 2 month, 4 month, and 12 month time points
|
Work functionality and impairment will be assessed over time using the Lam Employment and Productivity Scale (LEAPS).
|
The LEAPS will be assessed at baseline, 2 month, 4 month, and 12 month time points
|
|
Changes in mental health literacy
Time Frame: The MHL-Q will be assessed at baseline, 2 month, 4 month, and 12 month time points
|
Mental health literacy will be measured over time using the Mental Health Literacy questionnaire (MHL-Q).
|
The MHL-Q will be assessed at baseline, 2 month, 4 month, and 12 month time points
|
|
Changes in use of health services
Time Frame: The CSRI will be asssessed at screening, 4 month, and 12 month time points
|
Participants' use of health services will be assessed using the Client Service Receipt Inventory - modified (CSRI).
|
The CSRI will be asssessed at screening, 4 month, and 12 month time points
|
|
Changes in health status
Time Frame: The EQ-5D will be assessed at baseline, 2 month, 4 month, and 12 month time points
|
Health status will be assessed using the Euroquol-5 (EQ-5D).
|
The EQ-5D will be assessed at baseline, 2 month, 4 month, and 12 month time points
|
|
Changes in health status and health related quality of life
Time Frame: The HUI-3 will be assesed at baseline, 2 month, 4 month, and 12 month time points
|
Health status and health related quality of life will be assessed over time using the Health Utilities Index (HUI-3).
|
The HUI-3 will be assesed at baseline, 2 month, 4 month, and 12 month time points
|
|
Changes in illness severity
Time Frame: The DUSOI will be assessed at baseline, 2 month, 4 month, and 12 month time points
|
Illness severity will be assessed over time using the Duke Severity of Illness Checklist (DUSOI).
|
The DUSOI will be assessed at baseline, 2 month, 4 month, and 12 month time points
|
|
Client satisfaction.
Time Frame: The CSQ-9 will be assessed at 4 month time point.
|
Client satisfaction will be assessed using the Client Satisfaction Questionnaire 9 (CSQ-9).
|
The CSQ-9 will be assessed at 4 month time point.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mark Lau, PhD, University of British Columbia
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H08-02847
- 106504 (Other Grant/Funding Number: Canadian Institute of Health Research)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
Massachusetts General HospitalRecruitingDepression | Depression - Major Depressive Disorder | Depression Chronic | Depression in Adults | Depression Disorders | Depression DisorderUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)Active, not recruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
ProgenaBiomeWithdrawnDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Sorlandet Hospital HFUniversity of Oslo; Karolinska Institutet; Australian Catholic University; Helse...RecruitingAnxiety | Anxiety Depression | Depression Anxiety Disorder | Depression - Major Depressive DisorderNorway
-
Lipocine Inc.CompletedDepression, Postpartum | Postnatal Depression | Peripartum Depression | Depression, Post-Partum | Postpartum Depression (PPD) | Post-Natal DepressionUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Kolby Walker, DO; Brittany KimbleRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryActive, not recruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of CincinnatiNational Center for Complementary and Integrative Health (NCCIH)RecruitingMild DepressionUnited States
-
University of MinnesotaCompletedDepression SymptomsUnited States
Clinical Trials on Telephone-supported self-help and GP treatment as usual
-
Oslo University HospitalNorwegian Labour and Welfare Administration; Norwegian Directorate of HealthCompleted
-
Mayo ClinicTerminated
-
Imperial College LondonNational Institute for Health Research, United KingdomTerminated
-
Universita di VeronaUniversity of Turku; University of Vienna; World Health Organization; University... and other collaboratorsCompleted
-
Universität Duisburg-EssenCompletedPost-COVID-19 SyndromeGermany
-
University of EdinburghCompleted
-
University of Western Ontario, CanadaCanadian Institutes of Health Research (CIHR); Children's Hospital of Eastern...CompletedChild Behavior | Behavior Problems | Sleep ProblemsCanada
-
Semmelweis UniversityCompleted
-
University of CologneEli Lilly and CompanyCompletedAttention-Deficit/Hyperactivity DisorderGermany
-
Simon Fraser UniversityGrand Challenges Canada; Ministry of Labour - Invalids and Social AffairsCompleted